

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

99 AUG 13 AM 9:53

H.O.

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Parry and Romani Associates, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 233 Constitution Avenue, NE City Washington State/Zip (or Country) DC 20002 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Edward Baxter	Telephone 202-547-4000	E-mail (optional)	5. Senate ID # 30792-191
7. Client Name <input type="checkbox"/> Self Glaxo-Wellcome, Inc.	6. House ID #		

TYPE OF REPORT 8. Year **1999** Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ \$40,000.00 Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(c) of the Internal Revenue Code

Signature _____ Date **07/30/1999**

Printed Name and Title **Romano Romani - President** Page 1 of 4

Registrant Name: Parry and Romani Associates, Inc.

Client Name: Glaxo-Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

H.R. 1907, The American Inventors Protection Act of 1999., Support.

P.L. 98-417, Reform of the Drug Price Competition and Patent Term Restoration Act of 1984.,

17. House(s) of Congress and Federal agencies contacted
Department of Commerce, Patent and Trademark Office
House of Representatives
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Baxter, Edward		No
DeConcini, Dennis		No
Martin, Jack		No
Parry, Thomas		No
Romani, Romano		No
Skidany, Linda		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Glaxo Wellcome plc NONE

Signature _____

Date 07/30/1999

Printed Name and Title Romano Romani - President

Page 2 of 4

Registrant Name: Parry and Romani Associates, Inc.

Client Name: Glaxo-Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

S.578, Health Care Personal Information Nondisclosure Act of 1999, Interested in maintaining viability of medical and pharmaceutical research under medical records privacy legislation.

S.881, Medical Information Protection Act of 1999, Interested in maintaining viability of medical and pharmaceutical research under medical records privacy legislation.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Food & Drug Administration

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Baxter, Edward		No
DeConcini, Dennis		No
Hatch, Scott		No
Martin, Jack		No
Parry, Thomas		No
Romani, Romano		No
Skladany, Linda		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Glaxo Wellcome plc NONE

Signature _____

Date 07/30/1999

Printed Name and Title Romano Romani - President

Page 3 of 4

Registrant Name: Parry and Romani Associates, Inc.

Client Name: Glaxo-Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

No activity this reporting period.

17. House(s) of Congress and Federal agencies contacted

☒ Check if None

18. Name of each individual who acted as a lobbyist in this issue area


Name	Covered Official Position (if applicable)	New
Baxter, Edward		No
DeConcini, Dennis		No
Martin, Jack		No
Parry, Thomas		No
Romani, Romano		No
Skladany, Linda		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Glaxo Wellcome plc NONE

Signature



Date 07/30/1999

Printed Name and Title Romano Romani - President

Page 4 of 4